Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 19 analyst ratings
Hold
Strong Buy 16%
Buy 21%
Hold 58%
Sell 0%
Strong Sell 5%

Bulls say

Humana is uniquely positioned in the private health insurance sector due to its strong focus on government-sponsored programs, which make up over 95% of its revenue. The company's recent earnings report showed upside on cost trend development and a pragmatic approach to balancing reserve dynamics. This, combined with their commitment to margin preservation and enrollment growth, presents a strong case for a higher EPS baseline and potential earnings recapture in 2026-2027. Additionally, Humana's solid execution and potential for higher peer multiples justify a Buy rating.

Bears say

Humana is facing several challenges that may impede its growth potential in the long term. These include a limited market for its services (focused mainly on government-sponsored programs), potential increases in operating costs (as seen in Q1 where the company experienced higher-than-expected operating costs in their CenterWell segment), and concerns over their ability to achieve guided core MA margin improvement for FY26. These challenges could ultimately harm Humana's profitability and hinder its ability to maintain a strong market position.

Humana (HUM) has been analyzed by 19 analysts, with a consensus rating of Hold. 16% of analysts recommend a Strong Buy, 21% recommend Buy, 58% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 19 analysts, Humana (HUM) has a Hold consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $368.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $368.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.